The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- AZ’s Ticagrelor, Boehringer’s Triple Combo Added to MHLW Panel’s Review Agenda for May 27
May 24, 2016
- Takecab-Contained Blister Packs for H. pylori Eradication, Other Products to Join NHI Price List on May 25
May 24, 2016
- MHLW OKs Add’l Indications for Avastin, Other Drugs
May 24, 2016
- MHLW’s Expanded Development Request Scheme Gets Underway
May 23, 2016
- Lecture Fees Paid “Purely as Compensation” Would Not Be Subject to Regulation under New Clinical Research Bill: Health Policy Bureau Chief
May 23, 2016
- Govt’s Draft Economic Growth Strategy Embraces Use of Big Data by PMDA
May 20, 2016
- Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
May 20, 2016
- Clinical Research Bill to Make It Easier for Companies to Provide Unapproved Drugs for Clinical Programs: LDP Lawmaker
May 20, 2016
- Council Determines Parathyroid Hormone Preparation for Hypoparathyroidism Has High Unmet Medical Need
May 20, 2016
- MHLW Raises Caution for Use of Harvoni, 7 Other Hep C Drugs in HBV Carriers
May 19, 2016
- Clinical Research Bill to Enter Diet Deliberations on May 20, Might Be Enacted June 1
May 19, 2016
- MOF Panel Recommends Full Rollout of Cost-Effective Evaluations
May 19, 2016
- LDP Bigwig Questions Costly Meds Reimbursement without Politicians’ Input
May 19, 2016
- Draft of Govt’s Economic, Fiscal Policy Blueprint Mentions “Optimal Use of Innovative Drugs”
May 19, 2016
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.6%: Chuikyo
May 19, 2016
- Pricy Meds Again a Hot Topic at Chuikyo, MHLW Set to Launch Concrete Discussions
May 19, 2016
- AMED Initiates Project to Create Integrated Database for Clinical Genome Information
May 19, 2016
- Industry Opposes to Market Price Survey for Possible 2017 Revision; “No Reason to Conduct Survey if Sales Tax Hike Is Postponed”: FPMAJ Chairman
May 19, 2016
- Chuikyo OKs 16 APIs for Listing on May 25, Novartis’s Melanoma Combo Gets 45% Price Premium
May 18, 2016
- MHLW Advisory Panel to Discuss ASKA’s Hepatic Encephalopathy Treatment on May 30
May 18, 2016
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…